Evidence mapPaperPMID 42178367Full record

ArticleThe oncologist2026

The seventh kidney cancer research summit: progress in accelerating cures.

Toni K Choueiri, A Ari Hakimi, Rana McKay, Sumanta K Pal, Thomas Powles, Kevin Pels, Bryan Lewis, Susan Poteat, Hans Hammers

Abstract readConference Proceedings
In one paragraph

Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.ORCID 0000-0002-9201-3217
A Ari HakimiDepartment of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.ORCID 0000-0002-0930-8824
Rana McKayDepartments of Medicine and Urology, University of California San Diego, San Diego, CA 92037, United States.ORCID 0000-0002-0581-7963
Sumanta K PalDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States.ORCID 0000-0002-1712-0848
Thomas PowlesBarts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, United Kingdom.ORCID 0000-0001-7760-4724
Kevin PelsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.ORCID 0000-0002-3214-379X
Bryan LewisKidneyCAN, Philadelphia, PA 19118, United States.ORCID 0000-0002-9744-9247
Susan PoteatKidneyCAN, Philadelphia, PA 19118, United States.ORCID 0000-0001-8898-2034
Hans HammersDivision of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.ORCID 0000-0002-6224-4559

Funding

The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4M
Dana-Farber/Harvard Cancer Center Kidney SPORE 2P50CA101942-16Dana-Farber/Harvard Cancer Center Kidney SPORE 5P30CA006516-56Frank Shaughnessy Kidney Cancer Research FundKohlberg Chair at Harvard Medical School and the Trust FamilyLoker Pinard Funds for Kidney Cancer Research at DFCIMichael BrighamNCI NIH HHS P30 CA008748Pan Mass Challenge, Hinda and Arthur Marcus FundRoger and Kathy Marino Fund for Research Acceleration
6 · The paper itself

Abstract

The seventh Kidney Cancer Research Summit was held as a hybrid virtual/in-person event in Boston, MA during July 17-18, 2025. This conference, which aims to help guide the design of kidney cancer clinical trials and research, centers around projects that showcase the most impactful basic, translational, and clinical data evolving in renal cell carcinoma (RCC), and brings together clinical oncologists, physician scientists, translational researchers, and patient advocates. The abstract presentations were published as a supplement in The Oncologist (https://academic.oup.com/oncolo/issue/30/Supplement_2). This perspective will provide the layout of the current RCC research landscape as discussed and debated among the stakeholders at the conference as well as more recent updates.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHumansimmunotherapykidney cancerrenal cell carcinoma

Identifiers

PMID42178367
PMCPMC13281934

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.